Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biosimilars | Current Treatment | Oncology | US/EU | 2019

Login to access report north_east
Contact sales account_box

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-2018 and early-2019, trastuzumab biosimilars (Herzuma, Ontruzant, Kanjinti, Trazimera, and Ogivri)  expanded the biosimilar sector of the European oncology market. Uptake of these MAb biosimilars and biosimilars of granulocyte colony-stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) biosimilars will depend on the prescribing behavior of oncologists. To help manufacturers/marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Decision Resources Group has conducted primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.

Questions answered:

  • What is the current patient share of oncology biosimilars, and what expectations do oncologists have for future patient shares, assuming additional biosimilars launch?
  • How similar do oncologists believe biosimilars are to their reference brands?
  • What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
  • What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
  • What cost reduction is required for a biosimilar to achieve more than a 50% patient share?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Accord Healthcare
  • Amgen
  • Biogen
  • Bristol-Myers Squibb
  • Celltrion
  • Genentech
  • Merck
  • Novartis
  • Pfizer
  • Procrit
  • Sandoz
  • STADA
  • Roche
  • Teva

Key drugs mentioned:

  • Aranesp
  • Avastin
  • Binocrit
  • Epogen
  • Eprex
  • Erbitux
  • Erypo
  • Fulphila
  • Granix
  • Herceptin
  • Herzuma
  • Kanjinti
  • Lonquex
  • Mvasi
  • NeoRecormon
  • Neulasta
  • Neupogen
  • Nivestim/Nivestym
  • Ontruzant
  • Perjeta
  • Retacrit
  • Rituxan/MabThera
  • Rixathon
  • Silapo
  • Trazimera
  • Truxima
  • Udenyca
  • Vectibix
  • Yervoy
  • Zarzio/Zarxio
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
north_east
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
north_east
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
north_east
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
north_east
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east